In last trading session, ArriVent BioPharma Inc (NASDAQ:AVBP) saw 0.88 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $22.91 trading at $0.1 or 0.44% at ring of the bell on the day assigns it a market valuation of $783.81M. That closing price of AVBP’s stock is at a discount of -58.75% from its 52-week high price of $36.37 and is indicating a premium of 32.47% from its 52-week low price of $15.47. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.59 million shares which gives us an average trading volume of 306.87K if we extend that period to 3-months.
For ArriVent BioPharma Inc (AVBP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
ArriVent BioPharma Inc (NASDAQ:AVBP) trade information
Upright in the green during last session for gaining 0.44%, in the last five days AVBP remained trading in the red while hitting it’s week-highest on Monday, 06/23/25 when the stock touched $22.91 price level, adding 10.96% to its value on the day. ArriVent BioPharma Inc’s shares saw a change of 31.06% in year-to-date performance and have moved -9.16% in past 5-day. ArriVent BioPharma Inc (NASDAQ:AVBP) showed a performance of 14.32% in past 30-days. Number of shares sold short was 5.02 million shares which calculate 14.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 36 to the stock, which implies a rise of 36.36% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 36. It follows that stock’s current price would drop -52.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -52.77% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around -48.37% while estimates for its earnings growth in next 5 years are of 5.00%.
ArriVent BioPharma Inc (NASDAQ:AVBP)’s Major holders
Insiders are in possession of 9.74% of company’s total shares while institution are holding 85.20 percent of that, with stock having share float percentage of 94.40%. Investors also watch the number of corporate investors in a company very closely, which is 85.20% institutions for ArriVent BioPharma Inc that are currently holding shares of the company. HHLR ADVISORS, LTD. is the top institutional holder at AVBP for having 4.48 million shares of worth $83.19 million. And as of 2024-06-30, it was holding 13.3834 of the company’s outstanding shares.
The second largest institutional holder is ORBIMED ADVISORS LLC, which was holding about 3.03 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.0343 of outstanding shares, having a total worth of $56.16 million.
